Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso.

Se describe un caso clínico de un hombre de 69 años, hipertenso que recibió tratamiento con hidroclorotiaziada 25 mg día y desarrolló una reacción adversa compatible con una eritrodermia descamativa. El paciente experimentó mejoría clínica y resolución total de sus problemas cutáneos cuando finalizó...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:: 2022

Institución:: Universidad de Caldas

Repositorio:: Repositorio Institucional U. Caldas

Idioma:: spa

id	REPOUCALDA_efb04b183f7f6d53de3a2d981178182e
oai_identifier_str	oai:repositorio.ucaldas.edu.co:ucaldas/23661
network_acronym_str	REPOUCALDA
network_name_str	Repositorio Institucional U. Caldas
repository_id_str
dc.title.none.fl_str_mv	Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso. Aggressive scaly erytroderma, adverse reaction in a patient treated with hydrochlorothiazide: A case report.
title	Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso.
spellingShingle	Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso. diurético urticaria eritema farmacovigilancia (fuente: DeCS) diuretic urticaria erythema pharmacovigilance (source: MeSH).
title_short	Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso.
title_full	Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso.
title_fullStr	Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso.
title_full_unstemmed	Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso.
title_sort	Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso.
dc.subject.none.fl_str_mv	diurético urticaria eritema farmacovigilancia (fuente: DeCS) diuretic urticaria erythema pharmacovigilance (source: MeSH).
topic	diurético urticaria eritema farmacovigilancia (fuente: DeCS) diuretic urticaria erythema pharmacovigilance (source: MeSH).
description	Se describe un caso clínico de un hombre de 69 años, hipertenso que recibió tratamiento con hidroclorotiaziada 25 mg día y desarrolló una reacción adversa compatible con una eritrodermia descamativa. El paciente experimentó mejoría clínica y resolución total de sus problemas cutáneos cuando finalizó el uso de la hidroclorotiazida.
publishDate	2022
dc.date.none.fl_str_mv	2022-03-17T00:36:11Z 2022-03-17T00:36:11Z 2022-03-17 2025-10-08T21:16:02Z 2025-10-08T21:16:02Z
dc.type.none.fl_str_mv	Artículo de revista http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_dcae04bc Text info:eu-repo/semantics/article Journal article http://purl.org/redcol/resource_type/ARTREV info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
status_str	publishedVersion
dc.identifier.none.fl_str_mv	1657-9550 https://repositorio.ucaldas.edu.co/handle/ucaldas/23661 2462-960X https://revistasojs.ucaldas.edu.co/index.php/biosalud/article/view/4678
identifier_str_mv	1657-9550 2462-960X
url	https://repositorio.ucaldas.edu.co/handle/ucaldas/23661 https://revistasojs.ucaldas.edu.co/index.php/biosalud/article/view/4678
dc.language.none.fl_str_mv	spa
language	spa
dc.relation.none.fl_str_mv	117 2 113 13 Biosalud Beijer HJ, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24:46-54. Dormann H, Mulh-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalization: Computerized monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22:161-168. Chang YP, Huang SK, Tao P, Chien CW. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrology 2012; 13:96. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug related problems. Br J Clin Pharmacol 2007; 63:187-195. Moya Y, Bernal F, Rojas E, Barthel E. Seguimiento fármaco-terapéutico en pacientes ambulatorios con tratamiento anti-retroviral. Rev Chilena Infectol 2012; 29 (4): 412-419. Product Information. Tekturna HCT(R) oral tablets, aliskiren hydrochlorothiazide oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2012. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281:824-9. Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring. Center. J Rheumatol 2001; 28:1180-7. Karimi G, Star K, Norén GN, Hägg S. The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One 2013; 8(7):e68938. Rubin RL. Drug-induced lupus. In: Wallace DJ, Hahn B, Dubois EL, et al., eds. Dubois’ Lupus Erythematosus. 7th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2007; 7. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103:49-51. Richard R, Tigh J, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and Cutaneous T Cell Lymphoma Prospective Analysis and Case Series. Cancer 2013; 119:825-31. Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus British Journal of Dermatology 2011; 164:465-472. Han KD, Bark KM, Heo EP, Lee JK, Kang JS, Kim TH. Increased phototoxicity of hydrochlorothiazide by photodegradation. Photodermatol Photoimmunol Photomed 2000; 16:121-124. Bartolo L, Valverde J, Rojas P, Vicuña D. Eritrodermia adquirida en un adulto. Dermatol Perú 2010; 20(1):116-120. Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosisfungoidesa disease of antigen persistence. Br J Dermatol 1974; 91:607-616. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116:767-771. Schjott J, Bergman J. Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems. Drug, Healthcare and Patient Safety 2014; 6:89-92. Núm. 2 , Año 2014 : Julio - Diciembre https://revistasojs.ucaldas.edu.co/index.php/biosalud/article/download/4678/4268
dc.rights.none.fl_str_mv	Revista Biosalud - 2014 https://creativecommons.org/licenses/by-nc-sa/4.0/ info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	Revista Biosalud - 2014 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Universidad de Caldas
publisher.none.fl_str_mv	Universidad de Caldas
dc.source.none.fl_str_mv	https://revistasojs.ucaldas.edu.co/index.php/biosalud/article/view/4678
institution	Universidad de Caldas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1860877810757795840
spelling	Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso.Aggressive scaly erytroderma, adverse reaction in a patient treated with hydrochlorothiazide: A case report.diuréticourticariaeritemafarmacovigilancia (fuente: DeCS)diureticurticariaerythemapharmacovigilance (source: MeSH).Se describe un caso clínico de un hombre de 69 años, hipertenso que recibió tratamiento con hidroclorotiaziada 25 mg día y desarrolló una reacción adversa compatible con una eritrodermia descamativa. El paciente experimentó mejoría clínica y resolución total de sus problemas cutáneos cuando finalizó el uso de la hidroclorotiazida.The clinical case of a 69 year old man having high blood pressure who was treated with hydrochlorothiazide at 25 mg per day and who developed an adverse reaction compatible with scaly erythroderma is described. The patient underwent clinical recovery and total solution to his skin problems when the use of hydrochlorothiazide was susupended.Universidad de Caldas2022-03-17T00:36:11Z2025-10-08T21:16:02Z2022-03-17T00:36:11Z2025-10-08T21:16:02Z2022-03-17Artículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_dcae04bcTextinfo:eu-repo/semantics/articleJournal articlehttp://purl.org/redcol/resource_type/ARTREVinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1application/pdf1657-9550https://repositorio.ucaldas.edu.co/handle/ucaldas/236612462-960Xhttps://revistasojs.ucaldas.edu.co/index.php/biosalud/article/view/4678https://revistasojs.ucaldas.edu.co/index.php/biosalud/article/view/4678spa117211313BiosaludBeijer HJ, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24:46-54.Dormann H, Mulh-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalization: Computerized monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22:161-168.Chang YP, Huang SK, Tao P, Chien CW. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrology 2012; 13:96.Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug related problems. Br J Clin Pharmacol 2007; 63:187-195.Moya Y, Bernal F, Rojas E, Barthel E. Seguimiento fármaco-terapéutico en pacientes ambulatorios con tratamiento anti-retroviral. Rev Chilena Infectol 2012; 29 (4): 412-419.Product Information. Tekturna HCT(R) oral tablets, aliskiren hydrochlorothiazide oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2012.Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281:824-9.Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring. Center. J Rheumatol 2001; 28:1180-7.Karimi G, Star K, Norén GN, Hägg S. The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One 2013; 8(7):e68938.Rubin RL. Drug-induced lupus. In: Wallace DJ, Hahn B, Dubois EL, et al., eds. Dubois’ Lupus Erythematosus. 7th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2007; 7.Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103:49-51.Richard R, Tigh J, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and Cutaneous T Cell Lymphoma Prospective Analysis and Case Series. Cancer 2013; 119:825-31.Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus British Journal of Dermatology 2011; 164:465-472.Han KD, Bark KM, Heo EP, Lee JK, Kang JS, Kim TH. Increased phototoxicity of hydrochlorothiazide by photodegradation. Photodermatol Photoimmunol Photomed 2000; 16:121-124.Bartolo L, Valverde J, Rojas P, Vicuña D. Eritrodermia adquirida en un adulto. Dermatol Perú 2010; 20(1):116-120.Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosisfungoidesa disease of antigen persistence. Br J Dermatol 1974; 91:607-616.Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116:767-771.Schjott J, Bergman J. Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems. Drug, Healthcare and Patient Safety 2014; 6:89-92.Núm. 2 , Año 2014 : Julio - Diciembrehttps://revistasojs.ucaldas.edu.co/index.php/biosalud/article/download/4678/4268Revista Biosalud - 2014https://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Guzmán Terán, CamiloVilla Dangond, HiltonyTorres Ayazo, Omaroai:repositorio.ucaldas.edu.co:ucaldas/236612025-10-08T21:16:02Z

Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso.

Publicaciones similares